Capricor Therapeutics(CAPR)
Focus: Capricor Therapeutics is a San Diego-based public biotech specializing in allogeneic cell and exosome-based therapies for rare diseases, with a focus on cardiac and muscular dystrophy indications. The company operates at pre-revenue scale with an R&D-intensive model.
Profile data last refreshed 8h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
9-23 this month
Contracting — net -23 jobs in 30d
9 added, 32 removed. Active reduction in progress.
Should You Work at Capricor Therapeutics?
AI assessmentCapricor offers high scientific upside and rare-disease pedigree but carries pronounced liquidity and regulatory risk; suitable only for risk-tolerant scientists seeking pre-commercialization execution.
Why Work Here
- Exposure to cutting-edge cell therapy and exosome platforms in rare disease, a high-unmet-need segment with regulatory tailwinds and premium pricing potential.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$22M
Pipeline & Clinical Trials
CAP-1002 Allogeneic Cardiosphere-Derived Cells
COVID-19Clinical Trials (1)
NCT04338347CAP-1002 in Severe COVID-19 Disease
N/AHelp build intelligence for Capricor Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.